The National Institute for Health and Care Excellence (NICE) has today published final draft guidance recommending a new treatment for people with diabetic macular oedema (DMO). DMO is the most common ...

Left unmanaged, this diabetes-related complication can lead to vision changes. Implementing the right strategies can help you protect your eyesight. When high blood sugar levels related to diabetes ...

In the Phase Ib JADE trial, OLN324 demonstrated both faster and greater retinal drying versus Vabysmo in patients with DME, ...

Samsung Bioepis has started direct commercialisation of Byooviz, a biosimilar to Genentech’s Lucentis (ranibizumab), in ...

Diabetic macular edema (DME) occurs when fluid accumulates behind the macula, the part of your retina that processes central vision. DME can occur at any stage of diabetic retinopathy (DR). However, ...

Joseph M. Coney, MD, FACS, reviews best practices for improving adherence to treatment among patients with diabetic macular edema through comprehensive education on the disease and available therapies ...

March 26, 2007 – New York, NY -- The Juvenile Diabetes Research Foundation, the world’s largest charitable funder of type 1 diabetes research, announced that the Ranibizumab for Edema of the mAcula in ...

Exonate Ltd. (the Company), an mRNA therapy company focused on treatments for diabetic complications, today announced its lead ophthalmology asset, EXN407, has achieved its prespecified endpoints in a ...

CAMBRIDGE, England & NOTTINGHAM, England--(BUSINESS WIRE)--Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases ...

The National Institute for Health and Care Excellence (NICE) has recommended a new treatment option for people with diabetic macular oedema (DMO) with thousands of people set to benefit from the ...